Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen

Immunotherapy has shown limited success in prostate cancer; this may be partially explained by its immunosuppressive tumor microenvironment (TME). Although androgen-deprivation therapy (ADT), the most common treatment for prostate cancer, initially promotes a robust T cell infiltrate, T cell respons...

Full description

Bibliographic Details
Main Authors: Zoila A. Lopez-Bujanda, Matthew G. Chaimowitz, Todd D. Armstrong, Jeremy B. Foote, Leisha A. Emens, Charles G. Drake
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
cd8
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1809926